Incidence of pancreatic autoantibodies in primary sjÖgren syndrome
Bildiriler > Özet Bildiri · 2001
Yazarlar: Kenan AKSU, Gonca KARABULUT, Yasemin KABASAKAL, Gökhan KESER, Vedat İnal, A. IŞIK, Şevki ÇETİNKALP, Eker Doğanavşargil
Annals of the Rheumatic Diseases, Çek Cumhuriyeti, Prague, Uluslararası, Poster, Özet Bildiri, 2001-2001, ss 205-205
DOI: 10.1136/annrheumdis-2001.307
Özet
<p><strong>Background</strong> Primary Sjögren (SjS) syndrome is one of the prototypes of autoimmune diseases.</p><p><strong>Objectives</strong> We aimed to work out the incidence of pancreatic autoantibodies in this disease.</p><p><strong>Methods</strong> Seventy-six patients (F/M: 71/5, mean age: 49 ± 13 years) diagnosed as primary SjS syndrome according to the San Diego criteria between February 1997 and December 2000, have been included in the study. Twenty two, age matched (52 ± 10 years) female patients with secondary SjS due to rheumatoid arthritis were defined as the control group. Healthy control group included 22 age matched (F/M: 21/1) patients. Immunosuppressive drug usage, liver or renal failure were within the exclusion criteria. Serum samples for anti-insulin (AIA), islet (ICA) and anti-insulin receptor (IRA) antibodies were obtained from all patients after an 18 h fasting.</p><p><strong>Results</strong> The incidence of anti-insulin antibody was found as 17%, while it was 7% and%17 for islet antibodies and anti-receptor antibodies, respectively (<a href="https://ard.bmj.com/content/60/Suppl_1/A123.1#T1" rel="noopener noreferrer" target="_blank">Table 1</a>). These values were not statistically significant when compared with secondary SjS and healthy control groups (p > 0.05).</p>